Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Starpharma Holdings Limited ( (AU:SPL) ).
Starpharma Holdings Limited has announced significant progress in its strategic initiatives during the first quarter of FY26, highlighted by two major partnership agreements. The company signed a collaboration and license agreement with Genentech, a member of the Roche Group, for the development of DEP® cancer therapies, securing an upfront payment of USD $5.5 million and potential milestone payments up to USD $564 million. Additionally, a research and option agreement with Radiopharm Theranostics was established to develop a novel radiotherapy asset, marking Starpharma’s first radiopharmaceutical partnership. These agreements reflect growing industry validation of Starpharma’s DEP® platform, enhancing its commercial traction and positioning within the biotechnology sector. The company also received a $3.7 million R&D tax incentive refund and reported a cash balance of $14.3 million at the end of September 2025. Starpharma remains focused on advancing its DEP® HER2 radiopharmaceuticals program, expanding partnerships, and driving revenue growth through licensing and product sales.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company based in Melbourne, Australia, with over two decades of experience in advancing dendrimer technology. The company focuses on developing and commercializing its proprietary DEP® platform for oncology and other therapeutic areas, aiming to maximize the value of its assets through strategic partnerships and product sales.
Average Trading Volume: 1,066,264
Technical Sentiment Signal: Hold
Current Market Cap: A$135.9M
For an in-depth examination of SPL stock, go to TipRanks’ Overview page.